Understanding the heterogeneity of typical Alzheimer disease (AD) is of increasing importance for the development of new and effective treatments. A new study in patients with AD described two robust cognitive subtypes with different pathology distributions, genetic backgrounds and clinical trajectories.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Egan, M. F. et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 378, 1691–1703 (2018).
Honig, L. S. et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N. Engl. J. Med. 378, 321–330 (2018).
Rinne, J. O. et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 9, 363–372 (2010).
Sevigny, J. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 537, 50–56 (2016).
Jack, C. R. et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 14, 535–562 (2018).
Qiu, Y., Jacobs, D. M., Messer, K., Salmon, D. P. & Feldman, H. H. Cognitive heterogeneity in probable Alzheimer disease: clinical and neuropathologic features. Neurology 93, e778–e790 (2019).
Beach, T. G., Monsell, S. E., Phillips, L. E. & Kukull, W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J. Neuropathol. Exp. Neurol. 71, 266–273 (2012).
Dronse, J. et al. In vivo patterns of tau pathology, amyloid-β burden, and neuronal dysfunction in clinical variants of Alzheimer’s disease. J. Alzheimers Dis. 55, 465–471 (2017).
Hampel, H. et al. Revolution of Alzheimer Precision Neurology: passageway of systems biology and neurophysiology. J. Alzheimers Dis. 64 (Suppl. 1), S47–S105 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Jessen, F. Refining the understanding of typical Alzheimer disease. Nat Rev Neurol 15, 623–624 (2019). https://doi.org/10.1038/s41582-019-0259-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-019-0259-0
This article is cited by
-
Therapeutic Mechanism of Kai Xin San on Alzheimer’s Disease Based on Network Pharmacology and Experimental Validation
Chinese Journal of Integrative Medicine (2023)
-
Plasma neurofilament light levels correlate with white matter damage prior to Alzheimer’s disease: results from ADNI
Aging Clinical and Experimental Research (2022)
-
The Interplay of Tau Protein and β-Amyloid: While Tauopathy Spreads More Profoundly Than Amyloidopathy, Both Processes Are Almost Equally Pathogenic
Cellular and Molecular Neurobiology (2021)
